REDUCTIONS IN EXACERBATIONS IN PATIENTS WITH ALLERGIC (IGE-MEDIATED) ASTHMA RECEIVING OMALIZUMAB IN A REAL-WORLD SETTING

被引：0
|
作者：
Kuo, H. P. [1 ]
Canvin, J.
Maykut, R. [2 ]
Bruce, J. [2 ]
Chen, C. W. [3 ]
Braunstahl, G. J. [4 ]
机构：
[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Taipei, Taiwan
[2] Novartis Pharma AG, Zurich, Switzerland
[3] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[4] St Franciscus Gasthuis, Dept Pulm Med, Gasthuis, Netherlands
来源：
RESPIROLOGY | 2012年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
    Lowe, Philip J.
    Renard, Didier
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 306 - 320
  • [22] Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population
    Tarraf, Hesham N.
    Masoud, Hossam Hosny
    Zidan, Mohamed
    Wahba, Begad
    [J]. JOURNAL OF ASTHMA, 2020, 57 (02) : 160 - 166
  • [23] Real-life Effectiveness Of Omalizumab In Patients With Severe Persistent Allergic (IgE-Mediated) Asthma At A Single UK Hospital
    Simons, A.
    Regan, K.
    Aziz, A.
    Saralaya, D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [24] Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma
    Somerville, Laura
    Bardelas, Jose
    Viegas, Andrea
    D'Andrea, Peter
    Blogg, Martin
    Peachey, Guy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (01) : 59 - 66
  • [25] Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
    Mahashur, Ashok
    Talwar, Deepak
    Guleria, Randeep
    Kotnis, Mangala
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [26] Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
    Lowe, Philip J.
    Tannenbaum, Stacey
    Gautier, Aurelie
    Jimenez, Pablo
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 61 - 76
  • [27] Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
    Lee, Jason K.
    Amin, Suvina
    Erdmann, Michelle
    Kukaswadia, Atif
    Ivanovic, Jelena
    Fischer, Aren
    Gendron, Alain
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 725 - 735
  • [28] Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
    Kornmann, Oliver
    Watz, Henrik
    Fuhr, Rainard
    Krug, Norbert
    Erpenbeck, Veit J.
    Kaiser, Guenther
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2014, 28 (02) : 149 - 153
  • [29] Response of older patients with IgE-mediated asthma to omalizumab: A pooled analysis
    Maykut, Robert J.
    Kianifard, Farid
    Geba, Gregory P.
    [J]. JOURNAL OF ASTHMA, 2008, 45 (03) : 173 - 181
  • [30] The eXpeRience registry: The 'real-world' effectiveness of omalizumab in allergic asthma
    Braunstahl, G. -J.
    Chen, C-W
    Maykut, R.
    Georgiou, P.
    Peachey, G.
    Bruce, J.
    [J]. RESPIRATORY MEDICINE, 2013, 107 (08) : 1141 - 1151
12345